BTC $62,609.60 -0.24%
ETH $1,783.43 +0.35%
BNB $569.14 +0.16%
XRP $1.06 -0.63%
SOL $75.15 -1.68%
TRX $0.3248 -1.61%
DOGE $0.0722 +0.05%
ADA $0.1590 -0.68%
BCH $235.86 -0.23%
LINK $7.94 +0.06%
HYPE $63.73 -2.25%
AAVE $95.67 +1.28%
SUI $0.7321 +0.07%
XLM $0.1790 -2.03%
ZEC $507.46 -1.87%
BTC $62,609.60 -0.24%
ETH $1,783.43 +0.35%
BNB $569.14 +0.16%
XRP $1.06 -0.63%
SOL $75.15 -1.68%
TRX $0.3248 -1.61%
DOGE $0.0722 +0.05%
ADA $0.1590 -0.68%
BCH $235.86 -0.23%
LINK $7.94 +0.06%
HYPE $63.73 -2.25%
AAVE $95.67 +1.28%
SUI $0.7321 +0.07%
XLM $0.1790 -2.03%
ZEC $507.46 -1.87%

The US-listed company LIXTE has invested $2.6 million in cryptocurrency, increasing its allocation ratio to 50%

2025-09-11 08:26:51
Collection

ChainCatcher news, Nasdaq-listed company LIXTE Biotechnology Holdings (stock codes: LIXT and LIXTW) announced on September 10 that it has purchased 10.5 Bitcoin and 300 Ethereum for a total value of approximately $2.6 million as part of its diversification strategy.

According to the announcement, cryptocurrencies currently account for 43.6% of LIXTE's capital holdings, and the company's board has approved increasing the allocation of cryptocurrency to 50%. LIXTE Chairman and CEO Geordan Pursglove stated that this move aims to build a balanced and flexible digital asset strategy, enhancing the company's adaptability and long-term growth potential in the digital economy. Previously, it was reported that the U.S. listed biotech company LIXTE plans to allocate up to 25% of its capital reserves to digital assets such as Bitcoin.

app_icon
ChainCatcher Building the Web3 world with innovations.